New drugs and regimens for tuberculosis

Area of Science:

• Infectious Diseases
• Public Health
• Microbiology

Background:

• Standardized tuberculosis (TB) treatment regimens, though widely used, often lack timely adaptation to drug resistance profiles.
• Despite advances in diagnostics and therapeutics for drug-resistant TB, global public health challenges persist.
• Effective TB control necessitates integrated strategies encompassing diagnostics, tailored therapies, and management of risk factors.

Purpose of the Study:

• To review and discuss current approaches to tuberculosis treatment, focusing on standardized versus individualized therapies.
• To evaluate evidence for alternative regimens in drug-susceptible and multidrug-resistant TB (MDR-TB).
• To explore the role of repurposed and novel drugs in managing drug-resistant TB.

Main Methods:

• Comprehensive literature search on TB treatment strategies, drug resistance, diagnostics, and therapeutics.
• Analysis of standardized versus individualized treatment approaches, including the impact of rapid drug susceptibility testing.
• Review of evidence for WHO-recommended longer and shorter regimens for MDR-TB and the use of novel/repurposed drugs.

Main Results:

• The study highlights the limitations of one-size-fit-all treatment protocols in the face of evolving drug resistance.
• Evidence supports the exploration of individualized therapies guided by rapid drug susceptibility testing for optimal outcomes.
• Advances in diagnostics and therapeutics offer promising avenues for managing complex TB cases, including MDR-TB.

Conclusions:

• Optimizing TB control requires a synergistic approach combining rapid diagnostics, adaptable treatment regimens, and strong health systems.
• Individualized therapy, informed by drug resistance patterns, is essential for improving treatment efficacy and combating drug resistance.
• Future research should focus on developing biomarkers to guide personalized TB treatment and predict patient outcomes.